TZDs were designed in the late 1990s for the treatment of type 2 diabetes mellitus (T2DM), to regulate blood sugar levels and improve insulin sensitivity in patients with, and animal models of, T2DM [33]. The gene discussed is INS; the disease is diabetes mellitus.